Current rights and the limits of constitutional analogy
The Supreme Court has recognized protected interests in refusing medical interventions in some contexts, but an individual's choice to refuse treatment is not identical to a positive entitlement to obtain investigational products from suppliers or clinicians. The D.C. Circuit's en banc ruling in Abigail Alliance rejected a particular asserted fundamental due process right for terminally ill patients to obtain certain investigational drugs. That decision does not decide whether Congress may create an access pathway by statute. L01L03
Public rhetoric can invoke liberty, scientific self-determination, and a longstanding tradition of inquiry; the congressional legal memorandum must still distinguish an aspirational policy value from an existing constitutional holding. Overstating current rights is unnecessary and undermines the legislative pitch. The genuine claim is that Congress has room to reform a framework it helped create.
A reform's constitutional basis and statutory construction should identify interstate commerce in drugs and investigational services, conditions attached to federal research programs, protection of participant records where federal jurisdiction exists, and appropriate limits on federal administration. Precise congressional findings should explain the interstate research market, barriers experienced by small investigators, patient participation, and information-flow problems without asserting a nonexistent constitutional holding.
The Food, Drug, and Cosmetic Act and IND architecture
The central investigational drug provisions operate within the larger 21 USC §355 framework and FDA regulations including 21 CFR Part 312. Existing definitions of 'sponsor' and 'sponsor-investigator' already encompass individuals. Exemptions turn on criteria rather than on self-applied 'citizen science' or 'research use only' names. A legislative counsel draft could alter specified statutory predicates, require additional agency procedures, or authorize a tailored pilot with rulemaking and reporting. F01F02F12
Because §§312.2 and 312.40 are regulations, counsel must trace the statutory provisions they implement before deciding whether to amend a statute or require revised rulemaking. A statute that merely restates a definition already found in regulation accomplishes little. The key analytic work is to specify which present barrier remains after current IND, expanded access and Right to Try pathways are fully mapped. F01F03F11F22
Congress can also authorize procedural rights without changing substantive drug authorization: a defined response deadline, technical-assistance service, transparent complete-application checklist, publication of nonconfidential precedents, and a review route after a written denial. Those reforms can be evaluated on their own merits rather than bundled into an undefined exemption.
FDA consent and the distinction between law and policy
21 CFR §50.20 limits exculpatory language in FDA-regulated informed consent; §50.25 identifies information that must be disclosed. These rules govern covered investigations today. They are not a constitutional prohibition against every future narrow legislative choice, nor a reason to claim all risk can be waived by private contract. F07F08
A reform could require an optional standardized informed-uncertainty acknowledgement for investigational pathways, while expressly preserving causes of action for fraud, negligent conduct, contaminated supply, informed-consent violations, willful misconduct and product defects. Whether a particular defense should be created is a policy decision requiring evidence and state-law analysis, not a present fact.
Consent should not be framed as a moral substitute for independent review. The information asymmetry between technical investigators and ordinary volunteers calls for disclosure that is understandable, records of comprehension where important, accessible appeal and independent routes for reporting violations. Stronger participation rights and clearer responsibility can reinforce each other. F07F08F09
Federalism and preemption must be drafted with precision
State medical-practice licensing, pharmacy controls, professional liability, consumer protection, privacy, research regulations, and insurance rules may continue to apply even when a federal IND issue is resolved. Express preemption differs from implied conflict preemption, and no single preemption formula resolves every legal domain. The Supreme Court's Wyeth decision illustrates the fact-specific character of conflicts between FDA-related federal law and state tort duties. L02
A congressional drafting instruction should include a state-law impact table for each operative section: federal research authorization; clinical professional scope; product manufacture and dispensing; consent; negligence and injury; insurance; noncovered research data; and rights of action. For each, the bill should say what federal standard governs, what state law survives, who enforces a conflict, and what ordinary claimant remedies remain.
Qualified clinicians should receive clarity over authorized research participation without the law implying they are automatically licensed across states. Any national participation credential would raise distinct questions about professional licensure, disciplinary authority and telehealth. A narrower pilot could rely on clinicians already licensed where participants are located while gathering information for future reform.
What makes the legislation enforceable
A declaration that Americans 'have a right to research' might guide future interpretation, but it does not force an agency to answer an application or a data recipient to honor a withdrawal. Congress should assign duties using operative verbs, identify the actor, set measurable timing rules, state where an appeal lies, and provide for review or redress where appropriate.
Potential enforcement includes administrative reconsideration of a classification decision, public reporting of agency response time, Inspector General review of systemic delay, FTC or HHS enforcement for defined data practices, and limited private remedies for proven violations of statutory data or procedural rights. It is not safe to presume that existing FDA statutes already permit a general private lawsuit; a new cause of action must be consciously drafted.
The legislative counsel instructions should expose unresolved policy choices with bracketed alternatives rather than quietly choose one. The goal is clarity for lawmakers: which section changes FDA authorization, which funds services, which protects an adult participant, which protects a clinician, which establishes a hearing or remedy, and which merely expresses findings.